- Home
- ANTX vs CELU Comparison
ANTX vs CELU Comparison
Compare ANTX & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- CELU
- Stock Information
- Founded
- ANTX 2017
- CELU 2016
- Country
- ANTX United States
- CELU United States
- Employees
- ANTX N/A
- CELU N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- CELU Health Care
- Exchange
- ANTX Nasdaq
- CELU Nasdaq
- Market Cap
- ANTX 63.5M
- CELU 64.6M
- IPO Year
- ANTX 2022
- CELU N/A
- Fundamental
- Price
- ANTX $1.07
- CELU $2.65
- Analyst Decision
- ANTX Buy
- CELU
- Analyst Count
- ANTX 4
- CELU 0
- Target Price
- ANTX $2.50
- CELU N/A
- AVG Volume (30 Days)
- ANTX 204.5K
- CELU 16.5K
- Earning Date
- ANTX 11-07-2024
- CELU 11-10-2024
- Dividend Yield
- ANTX N/A
- CELU N/A
- EPS Growth
- ANTX N/A
- CELU N/A
- EPS
- ANTX N/A
- CELU N/A
- Revenue
- ANTX N/A
- CELU $22,771,000.00
- Revenue This Year
- ANTX N/A
- CELU N/A
- Revenue Next Year
- ANTX N/A
- CELU $233.89
- P/E Ratio
- ANTX N/A
- CELU N/A
- Revenue Growth
- ANTX N/A
- CELU 26.68
- 52 Week Low
- ANTX $0.87
- CELU $1.59
- 52 Week High
- ANTX $22.22
- CELU $7.97
- Technical
- Relative Strength Index (RSI)
- ANTX 39.40
- CELU 41.46
- Support Level
- ANTX $1.03
- CELU $2.56
- Resistance Level
- ANTX $1.09
- CELU $3.00
- Average True Range (ATR)
- ANTX 0.04
- CELU 0.22
- MACD
- ANTX 0.03
- CELU -0.02
- Stochastic Oscillator
- ANTX 66.67
- CELU 21.39
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.